GlobeNewswire Inc | Oct 21, 2021 04:05PM EDT

October 21, 2021

SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, announced today it will be presenting new scientific research at the American College of Rheumatologys (ACR) virtual annual meeting, ACR Convergence 2021. The event is being held online from November 6-9, 2021.

Exagens Chief Scientific Officer, Anja Kammesheidt, shared, Exagen is honored to have had the opportunity to partner with such great collaborators on this years abstracts. Our clinical research and development teams are committed to advancing the understanding of the role of cell-bound complement activation products (CB-CAPs) in lupus, and to contribute to advancing patient care. We are pleased to be sharing this data at this years virtual ACR event.

Below is the list of accepted abstracts along with links to each:

Saturday, November 6th

Poster Presentation | Presented by Roberta Alexander, PharmD, PhD | Abstract #0325Title A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus SessionTitle SLE Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323-0356)Session Time: 8:30am 10:30am ET

Poster Presentation | Presented by Richard Ramonell, MD | Abstract #0003Title Clinically Identifiable Autoreactivity is Common in Severe SARS-CoV-2 Infection SessionTitle B Cell Biology & Targets in Autoimmune & Inflammatory Disease PosterSession Time: 8:30am 10:30am ET

Poster Presentation | Presented by Matthew Woodruff, PhD | Abstract #0010Title Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19SessionTitle B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster Session Time: 8:30am 10:30am ET

Poster Presentation | Presented by Tyler OMalley, BS | Abstract #0336Title The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products Versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE SessionTitle SLE Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323-0356) Session Time: 8:30am 10:30am ET

Sunday, November 7th

Poster Presentation | Presented by Jennifer Rogers, MD | Abstract #0868Title Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE ActivitySessionTitle SLE Diagnosis, Manifestations, & Outcomes Poster II: Diagnosis (0855-0896) Session Time: 8:30am 10:30am ET

Poster Presentation | Presented by Kai Sun, MD | Abstract #0877Title Association of HCQ Blood Levels with Type 1 and 2 SLE ActivitySessionTitle SLE Diagnosis, Manifestations, & Outcomes Poster II: Diagnosis (0855-0896)Session Time: 8:30am 10:30am ET

Monday, November 8th

Poster Presentation | Presented by Mark Rudolph, PhD | Abstract #1086Title Lack of Effect of SARS-CoV-2 Vaccination on Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm and Inflammatory Biomarkers SessionTitle Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083-1117)Session Time: 8:30am 10:30am ET

Tuesday, November 9th

Poster Presentation | Presented by Kelley Brady, B.S. | Abstract #1764Title Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients SessionTitle SLE Treatment Poster (1732-1772)Session Time: 8:30am 10:30am ET

AboutExagen Inc.

Exagenis dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.Exagenhas developed and is commercializing a portfolio of innovative testing products under its AVISE brand. Several of these products are based on our proprietary CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagens goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagens model of integrating testing products and therapeutics positionsExagento offer targeted solutions to rheumatologists and, ultimately, better serve patients. For more information, please visitwww.Exagen.com

Forward Looking Statements

Exagencautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the companys current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding our clinical research and development teams commitment to advancing the understanding of the role of CB-CAPs in lupus, and its contribution to advancing patient care, scientific abstracts for presentation at ACR Annual Conference and the potential to lead to increased adoption of any AVISE test. The inclusion of forward-looking statements should not be regarded as a representation byExagenthat any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagens business, including, without limitation: the COVID-19 pandemic may continue to adversely affect our business, financial condition and results of operations, including as a result of shutdowns of our facilities and operations as well as those of our suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in ongoing and planned clinical trials involving our tests; the companys commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community; the companys ability to successfully execute on its business strategies, including its strategy of integrating the promotion of its existing and future proprietary testing products with the promotion of therapeutics; third party payers not providing coverage and adequate reimbursement for the companys testing products or promoted therapeutics; the companys ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting the companys business; and other risks described in the companys prior press releases and the companys filings with theSecurities and Exchange Commission(SEC), including under the heading Risk Factors in the companys Annual Report on Form 10-K for the year ended December 31, 2020 and any subsequent filings with theSEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, andExagenundertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations

Exagen Inc. Ryan Douglasrdouglas@exagen.com 760.560.1525

Company Exagen Inc. Kamal Adawi, Chief Financial Officerkadawi@exagen.com 760.477.5514